Titre : | Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe (2018) |
Auteurs : | H. FRASER ; N. K. MARTIN ; H. BRUMMER-KORVENKONTIO ; P. CARRIERI ; O. DALGARD ; J. DILLON ; D. GOLDBERG ; S. HUTCHINSON ; M. JAUFFRET-ROUSTIDE ; M. KABERG ; A. A. MATSER ; M. MATICIC ; H. MIDGARD ; V. MRAVCIK ; A. OVREHUS ; M. PRINS ; J. REIMER ; G. ROBAEYS ; B. SCHULTE ; D. K. VAN SANTEN ; R. ZIMMERMANN ; P. VICKERMAN ; M. HICKMAN |
Type de document : | Article : Périodique |
Dans : | Journal of Hepatology (Vol.68, n°3, March 2018) |
Article en page(s) : | 402-411 |
Note générale : | Editorial: Achieving hepatitis C elimination in Europe - To treatment scale-up and beyond. Hellard M., Scott N., Sacks-Davis R., Pedrana A., p. 383-385. |
Langues: | Anglais |
Discipline : | MAL (Maladies infectieuses / Infectious diseases) |
Mots-clés : |
Thésaurus mots-clés PRODUIT ILLICITE ; HEPATITE ; USAGER ; INJECTION ; TRAITEMENT ; PREVENTION ; PREVALENCE ; MODELE ; INCIDENCE |
Résumé : |
BACKGROUND & AIMS: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of current and scaled-up HCV treatment with and without scaling up opioid substitution therapy (OST) and needle and syringe programmes (NSPs) across Europe over the next 10years.
METHODS: We collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST, and NSP coverage from 11 European settings. We parameterised an HCV transmission model to setting-specific data that project chronic HCV prevalence and incidence among PWID. RESULTS: At baseline, chronic HCV prevalence varied from 55% (Finland/Sweden), and CONCLUSIONS: The scale-up of HCV treatment and other interventions is needed in most settings to minimise HCV transmission among PWID in Europe. LAY SUMMARY: Measuring the amount of HCV in the population of PWID is uncertain. To reduce HCV infection to minimal levels in Europe will require scale-up of both HCV treatment and other interventions that reduce injecting risk (especially OST and provision of sterile injecting equipment). Highlights: Chronic HCV prevalence and treatment rates among PWID vary widely across Europe. HCV treatment scale-up is required in most sites to reduce HCV transmission. Increasing OST/NSP coverage enhances HCV treatment prevention benefit. |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 49 |
Affiliation : | Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK |
URL : | Editorial |
Lien : | https://doi.org/10.1016/j.jhep.2017.10.010 |
Accueil